18 completed, 11 recruiting, 8 active not recruiting, 3 not yet recruiting. 16 Phase 3, 10 Phase 4, 3 Phase 2, 2 Not applicable, 1 Phase 1.
Follow Inclisiran: new trials by email Literature Review of Inclisiran trials Research Report on Inclisiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary Syndrome Inclisiran, Atorvastatin or Rosuvastatin, Ezetimibe - Acute Coronary Syndromes (ACS) | Phase 4 | Not yet recruiting | Seoul National University Bundang Hospital | 294 | 2026-11-30 | 2026-11-18 |
| Comparing Inclisiran Versus Statin for Primary Aldosteronism inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug) - Primary Aldosteronism | Not applicable | Recruiting | Third Military Medical University | 50 | 2026-11-15 | 2026-11-12 |
| Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia inclisiran, SOC - Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 300 | 2026-10-31 | 2026-10-30 |
| A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia QCZ484, Inclisiran, QCZ484 placebo - Hypercholesterolaemia | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-05-29 | 2026-07-30 |
| Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 4 | Recruiting | University Medical Centre Ljubljana | 60 | 2026-05-18 | 2026-06-02 |
| Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes Placebo, Inclisiran - Acute Coronary Syndrome | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 305 | 2025-10-03 | 2026-11-17 |
| Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) Inclisiran - Primary Hypercholesterolemia or Mixed Dyslipidemia | Recruiting | Novartis Pharmaceuticals | 1500 | 2025-08-13 | 2025-12-22 | |
| Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study Inclisiran - Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia | Active not recruiting | Novartis Pharmaceuticals | 219 | 2025-06-16 | 2026-08-07 | |
| Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice Alirocumab 150 mg, Inclisiran - Atherosclerotic Cardiovascular Disease | Completed | Sanofi | 996 | 2025-05-22 | 2026-10-13 | |
| Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD Pelacarsen, Placebo, Inclisiran - Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 246 | 2025-04-30 | 2026-10-14 |
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia Atorvastatin, Simvastatin, Rozuvastatin - Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 2382 | 2025-04-15 | 2026-11-13 | |
| Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia Inclisiran, Placebo - Familial Hypercholesterolemia - Homozygous | Phase 3 | Recruiting | Novartis Pharmaceuticals | 9 | 2025-02-28 | 2026-07-24 |
| LATAM LOWERS LDL-C Usual care, KJX839 - Hypercholesterolaemia | Phase 4 | Recruiting | Novartis Pharmaceuticals | 520 | 2025-02-11 | 2025-12-30 |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 4 | Active not recruiting | Duke University | 130 | 2024-12-16 | 2026-07-29 |
| Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia Inclisiran, Placebo - Familial Hypercholesterolemia - Heterozygous | Phase 3 | Recruiting | Novartis Pharmaceuticals | 60 | 2024-12-09 | 2026-05-15 |
| A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia inclisiran - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 4 | Completed | Novartis Pharmaceuticals | 65 | 2024-11-12 | 2026-06-23 |
| Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound Inclisiran - Carotid Plaque, Hyperlipidemia | Phase 4 | Unknown | First Affiliated Hospital of Xinjiang Medical University | 40 | 2024-09-20 | 2024-09-19 |
| The Prevent Coronary Artery Disease Trial Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 1600 | 2024-09-12 | 2025-04-29 |
| Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction atorvastatin, IVUS/OCT, inclisiran - Plaque, Atherosclerotic | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 318 | 2024-07-09 | 2026-07-28 |
| Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease Inclisiran - Ischemic Heart Disease, Acute Coronary Syndrome | Phase 4 | Not yet recruiting | Jose Seijas Amigo | 50 | 2024-06-01 | 2024-05-20 |
Showing 20 of 43. Sign in to see all of them.
Atherosclerosis (20) · Hypercholesterolemia (16) · Hyperlipidemias (8) · Hyperlipoproteinemia Type II (7) · Acute Coronary Syndrome (5) · Cardiovascular Diseases (4) · Homozygous Familial Hypercholesterolemia (4) · Plaque, Atherosclerotic (3) · Aortic Valve Stenosis (2) · Dyslipidemias (2) · Heart Failure (2) · Carotid Stenosis (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Hyperaldosteronism (1)
Novartis Pharmaceuticals (26) · The Medicines Company (3) · Duke University (1) · Federico II University (1) · First Affiliated Hospital of Xinjiang Medical University (1) · Icahn School of Medicine at Mount Sinai (1) · Jose Seijas Amigo (1) · LIB Therapeutics LLC (1) · Pauls Stradins Clinical University Hospital (1) · Sanofi (1) · Seoul National University Bundang Hospital (1) · Third Military Medical University (1) · University Medical Centre Ljubljana (1) · University of Cambridge (1) · University of Louisville (1)
United States (18) · United Kingdom (12) · Germany (11) · China (9) · Netherlands (9) · Spain (9) · Canada (7) · France (7) · Malaysia (6) · Greece (5) · Hungary (5) · Italy (5) · South Africa (5) · Taiwan (5) · Turkey (Türkiye) (5)
David Preiss (1) · Dinesh Kalra, MD (1) · Evan A Stein, MD PhD (1) · Frederick J. Raal, MD (1) · Jan Kafol, MD (1) · Jason M Tarkin, MBBS PhD (1) · Karlis Trusinskis, MD (1) · Kausik K Ray, MD (1) · Kausik Ray, MD (1) · Louise Bowman (1) · Marion Mafham (1) · Neha Pagidipati, MD (1) · Richard Robson, PhD (1) · Valentin Fuster, MD, PhD (1)
PMID 33990512, PMID 31630870, PMID 35175352, PMID 38063346, PMID 28306389, PMID 29735484, PMID 30487231, PMID 31553410, PMID 32197277, PMID 36620965, PMID 38593947, PMID 38757725, PMID 39053958, PMID 40010816, PMID 40391436, PMID 40392667, PMID 41604274, PMID 41616799, PMID 42132192, PMID 42567431
2016 (1), 2017 (1), 2025 (1)